Efficacy and Safety Study of MK0359 in Patients With Arthritis (0359-017)

Merck Sharp & Dohme (MSD)

Status and phase: Completed; Phase 2

Conditions: Rheumatoid Arthritis

Treatments: Drug: MK0359

Study type: Interventional

Funder types: Industry

Identifiers

NCT00482417

0359-017

2007_573

Details and patient eligibility

About

Efficacy and Safety Study of MK0359 in Patients with Arthritis

Enrollment: 11 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• You are 18-65 years of age and have Rheumatoid Arthritis
• You must be able to read and understand patient questionnaires

Exclusion criteria

• You have had certain types of surgery, certain types of cancer or history of Tuberculosis (TB) or HIV.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind